Skip to main content
    N

    NextCure  Inc (NXTC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.68
    +0.28 (+4.38%)

    Market Cap: $29.31M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    NextCure  Inc (NXTC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    NextCure reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$55.84M, operating cash flow was -$49.61M and free cash flow was -$49.61M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$6.85M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $57.62M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$22.38M+252.6%100.0%-184.2%-163.6%
    Dec 2019$6.35MN/A100.0%-590.5%-531.5%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$0$0$0$0$0$22.38M$6.35M$0$0
    Cost of revenue$0$0$0$0$0$0$0$1.68M$582.00K
    Gross profit$0$0$0$0$0$22.38M$6.35M-$1.68M-$582.00K
    Research and development$44.92M$41.49M$47.93M$54.20M$50.19M$46.55M$34.22M$19.79M$12.95M
    Operating income-$57.62M-$59.75M-$67.64M-$75.91M-$70.77M-$41.23M-$37.48M-$23.20M-$15.55M
    Net income-$55.84M-$55.65M-$62.72M-$74.73M-$69.39M-$36.60M-$33.74M-$22.80M-$15.47M
    EBITDA-$54.14M-$54.02M-$64.71M-$67.56M-$62.19M-$33.19M-$31.05M-$21.10M-$14.97M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$3.28M$0$0$0$6.28M
    Gross profit$0$0$0-$365.00K$0$0$0$1.64M$0$0$0$5.46M
    Operating income-$6.92M-$15.09M-$10.11M-$9.76M-$8.95M-$27.29M-$11.62M-$12.46M-$12.49M-$16.49M-$18.30M-$15.79M
    Net income-$6.85M-$14.89M-$9.80M-$9.44M-$8.62M-$26.81M-$10.98M-$11.60M-$11.54M-$15.40M-$17.11M-$14.47M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.00M by $24.98M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$50.18M$80.86M$128.04M$184.16M$242.39M$306.64M$356.17M$147.63M$19.47M
    Current assets$43.75M$71.81M$112.72M$163.98M$227.82M$287.98M$340.00M$135.78M$9.42M
    Cash and equivalents$25.98M$27.73M$13.08M$26.63M$12.34M$32.77M$34.09M$135.17M$8.43M
    Total liabilities$15.24M$15.39M$13.62M$16.63M$9.00M$12.92M$34.68M$32.35M$43.88M
    Short-term debt$1.00M$796.00K$656.00K$518.00KN/A$1.67M$1.67M$387.00K$504.00K
    Long-term debtN/AN/AN/AN/AN/A$1.81M$3.33M$73.00K$460.00K
    Shareholder equity$34.94M$65.47M$114.42M$167.53M$233.39M$293.72M$321.48M-$46.94M-$24.41M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$9.70M$22.62M$37.98M$50.18M$39.61M$47.69M$67.14M$80.86M$90.34M$102.59M$115.16M$128.04M
    Total liabilities$4.20M$10.47M$11.26M$15.24M$15.97M$16.04M$11.28M$15.39M$14.75M$17.15M$16.11M$13.62M
    Cash and equivalents$8.73M$15.26M$15.17M$25.98M$7.32M$4.89M$21.83M$27.73M$27.70M$20.85M$18.36M$13.08M
    Shareholder equity$5.50M$12.15M$26.72M$34.94M$23.65M$29.65M$55.85M$65.47M$75.59M$85.44M$99.05M$114.42M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$49.61M-$40.80M-$52.97M-$53.89M-$57.28M-$44.95M-$35.62M$7.99M-$12.51M
    Capital expenditures$0$474.00K$820.00K$2.12M$2.36M$7.13M$3.37M$3.06M$8.65M
    Free cash flow-$49.61M-$41.28M-$53.79M-$56.00M-$59.64M-$52.09M-$38.99M$4.93M-$21.17M
    Investing cash flow$25.56M$55.31M$39.27M$67.98M$36.60M$43.52M-$303.92M-$3.06M-$8.65M
    Financing cash flow$22.31M$144.00K$154.00K$200.00K-$3.27M-$1.42M$243.04M$121.42M$24.86M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$12.07M-$9.71M-$13.36M-$7.64M-$6.27M-$22.71M-$12.99M-$6.97M-$11.45M-$9.78M-$12.61M-$10.67M
    Capital expendituresN/AN/A$0$0$0$0$0$34.00K$170.00K$301.00K$37.00K$13.00K
    Free cash flowN/AN/A-$13.36M-$7.64M-$6.27M-$22.71M-$12.99M-$7.00M-$11.62M-$10.08M-$12.64M-$10.68M
    Last 12 quarters

    Frequently Asked Questions About NXTC

    What is NextCure's annual revenue?

    NextCure reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is NextCure profitable?

    No. NextCure reported net income of -$55.84M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does NXTC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$49.61M minus capital expenditures of $0 produced free cash flow of -$49.61M.

    How much debt does NextCure have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.00M and cash and equivalents of $25.98M.